EA202092065A1 - ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA) - Google Patents

ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)

Info

Publication number
EA202092065A1
EA202092065A1 EA202092065A EA202092065A EA202092065A1 EA 202092065 A1 EA202092065 A1 EA 202092065A1 EA 202092065 A EA202092065 A EA 202092065A EA 202092065 A EA202092065 A EA 202092065A EA 202092065 A1 EA202092065 A1 EA 202092065A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pspa
expression
surface protein
pneumococcal surface
discloses
Prior art date
Application number
EA202092065A
Other languages
English (en)
Inventor
Раджан Срираман
Рамеш Венкат Матур
Нарендер Дев Мантена
Махима Датла
Светха Камиредди
Original Assignee
Байолоджикал И Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байолоджикал И Лимитед filed Critical Байолоджикал И Лимитед
Publication of EA202092065A1 publication Critical patent/EA202092065A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к экспрессии пневмококкового поверхностного белка A (PspA). Изобретение представляет собой усовершенствование в области генной инженерии и технологии вакцин. В изобретении раскрыты экспрессионные векторы и рекомбинантные клетки-хозяева для экспрессии усеченного пептида PspA. В изобретении также раскрыты вакцинные композиции, содержащие усеченные пептиды в качестве белка-носителя.
EA202092065A 2018-03-01 2019-03-01 ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA) EA202092065A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841007814 2018-03-01
PCT/IB2019/051655 WO2019167008A1 (en) 2018-03-01 2019-03-01 Expression of pneumococcal surface protein a (pspa)

Publications (1)

Publication Number Publication Date
EA202092065A1 true EA202092065A1 (ru) 2020-11-19

Family

ID=66440079

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092065A EA202092065A1 (ru) 2018-03-01 2019-03-01 ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)

Country Status (18)

Country Link
US (2) US11725029B2 (ru)
EP (1) EP3758746A1 (ru)
JP (2) JP7334176B2 (ru)
KR (1) KR20200129121A (ru)
CN (1) CN112118865A (ru)
AU (1) AU2019226487A1 (ru)
BR (1) BR112020017431A2 (ru)
CA (1) CA3091583A1 (ru)
CL (1) CL2020002246A1 (ru)
CU (1) CU24709B1 (ru)
EA (1) EA202092065A1 (ru)
IL (1) IL277023A (ru)
MX (1) MX2020009049A (ru)
PH (1) PH12020551357A1 (ru)
SA (1) SA520420041B1 (ru)
SG (1) SG11202008124XA (ru)
WO (1) WO2019167008A1 (ru)
ZA (1) ZA202005414B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3231684A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
JP4712716B2 (ja) * 2004-09-09 2011-06-29 財団法人地球環境産業技術研究機構 プロモーター機能を有するｄｎａ断片
KR101813824B1 (ko) 2008-06-25 2017-12-29 벡션 테라퓨틱스 엘엘씨 조절된 유전자 자살 메커니즘 조성물 및 방법
WO2010141312A2 (en) * 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN107674118A (zh) * 2016-08-02 2018-02-09 中国食品药品检定研究院 重组蛋白PspA1、PspA2和PspA3以及包含其的多糖结合疫苗

Also Published As

Publication number Publication date
CA3091583A1 (en) 2019-09-06
WO2019167008A1 (en) 2019-09-06
ZA202005414B (en) 2022-02-23
US20210009641A1 (en) 2021-01-14
JP2023154063A (ja) 2023-10-18
SA520420041B1 (ar) 2024-03-14
IL277023A (en) 2020-10-29
CN112118865A (zh) 2020-12-22
AU2019226487A1 (en) 2020-09-10
CL2020002246A1 (es) 2021-01-15
US20230322871A1 (en) 2023-10-12
SG11202008124XA (en) 2020-09-29
JP7334176B2 (ja) 2023-08-28
BR112020017431A2 (pt) 2021-01-19
CU20200064A7 (es) 2021-04-07
MX2020009049A (es) 2020-10-12
KR20200129121A (ko) 2020-11-17
EP3758746A1 (en) 2021-01-06
PH12020551357A1 (en) 2021-08-23
JP2021516050A (ja) 2021-07-01
US11725029B2 (en) 2023-08-15
CU24709B1 (es) 2024-06-11

Similar Documents

Publication Publication Date Title
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
MX2019009720A (es) Metodos y composiciones para la transferencia de genes a traves de la vasculatura.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
UA120917C2 (uk) Химерний білок фактора viii та його застосування
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
MX2022015081A (es) Variantes de hsd17b13 y usos de las mismas.
BR112021018776A2 (pt) Vetores de vírus adenoassociado recombinante
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
MX2020010466A (es) Vectores de virus que evitan anticuerpos.
AR091735A1 (es) Complejo de factor viii con xten y proteina factor de von willebrand (vwf) y usos del mismo
EA201391331A1 (ru) Активные и селективные ингибиторы nav1.3 и nav1.7
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA202091352A1 (ru) Генотерапия мукополисахаридоза iiib
EA202092065A1 (ru) ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA)
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
MX2022013963A (es) Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
MX2021015698A (es) Integración dirigida de configuraciones aleatorias de ácidos nucleicos.
ZA202308985B (en) Constructs and methods for increased expression of polypeptides
CO2022004535A2 (es) Secuencia de extensión n-terminal para la expresión de péptidos terapéuticos recombinantes
MX2023012707A (es) Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos.
AR124651A1 (es) Vectores de aav dirigidos a linfocitos t
EA201790362A1 (ru) Солюбилизированный фермент и его применения
ES2663386T3 (es) Novirabdovirus recombinante utilizable como vector de antígenos